Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 71 entries
View as:

Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03647111 Org: User:
Start: 01/01/18 End: 12/01/25 Due: 12/01/26

Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC)

Phase: N/A Priority: Normal
NCT ID: NCT01991418 Org: User:
Start: 05/31/13 End: 02/29/16 Due: 02/28/17

Efficacy and Safety of Immunotherapy in Non-small Cell Lung Cancer With Uncommon Histological Type

Phase: N/A Priority: Normal
NCT ID: NCT05023837 Org: User:
Start: 03/02/18 End: 08/03/21 Due: 08/03/22

Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03647592 Org: User:
Start: 06/01/18 End: 12/01/25 Due: 12/01/26

Correlation Research of Thioredoxin Reductase in Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01985113 Org: User:
Start: 05/31/13 End: 02/29/16 Due: 02/28/17

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT04324164 Org: User:
Start: 03/24/20 End: 12/24/27 Due: 12/24/28

Survival Outcomes of Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03647098 Org: User:
Start: 08/01/18 End: 12/31/30 Due: 12/31/31

Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02399566 Org: User:
Start: 05/31/15 End: 01/31/19 Due: 01/31/20

Association Between the Results of Specific Genetic Tests and the Efficacy of Targeted Therapies in Patients

Phase: N/A Priority: Normal
NCT ID: NCT05450081 Org: User:
Start: 06/30/22 End: 10/01/23 Due: 10/01/24

Local Radiotherapy for Residual Tumor Lesions During the First-line Treatment

Phase: N/A Priority: Normal
NCT ID: NCT05205226 Org: User:
Start: 01/02/18 End: 01/02/22 Due: 01/02/23

Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05059951 Org: User:
Start: 10/03/21 End: 03/01/28 Due: 03/01/29

Tumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01980212 Org: User:
Start: 05/01/13 End: 12/01/18 Due: 12/01/19

Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05296603 Org: User:
Start: 12/03/21 End: 12/25/25 Due: 12/25/26

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

Phase: N/A Priority: Normal
NCT ID: NCT02098954 Org: User:
Start: 07/01/14 End: 12/12/25 Due: 12/12/26

Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers

Phase: N/A Priority: Normal
NCT ID: NCT02161991 Org: User:
Start: 02/01/14 End: 01/31/18 Due: 01/31/19

The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.

Phase: N/A Priority: Normal
NCT ID: NCT04777084 Org: User:
Start: 08/01/21 End: 12/25/25 Due: 12/25/26

Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung Cancers

Phase: N/A Priority: Normal
NCT ID: NCT02166242 Org: User:
Start: 06/01/14 End: 12/01/21 Due: 12/01/22

Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression

Phase: N/A Priority: Normal
NCT ID: NCT07001995 Org: User:
Start: 10/01/25 End: 10/30/28 Due: 10/30/29

Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05991180 Org: User:
Start: 12/25/23 End: 12/31/25 Due: 12/31/26

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06348927 Org: User:
Start: 07/01/24 End: 04/30/27 Due: 04/30/28

Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB

Phase: N/A Priority: Normal
NCT ID: NCT05295212 Org: User:
Start: 02/01/23 End: 07/01/25 Due: 07/01/26

Diffusion-weighted Magnetic Resonance Imaging (DW-MRI )for Early Response Assessment in Patients With Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02527057 Org: User:
Start: 10/31/14 End: 12/31/19 Due: 12/31/20

The Efficacy and Safety of IBI363 in Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06081907 Org: User:
Start: 12/25/23 End: 09/01/28 Due: 09/01/29

The Prediction Biomarkers of Survival Outcome for Severe Immune-related Hepatitis

Phase: N/A Priority: Normal
NCT ID: NCT05326906 Org: User:
Start: 05/01/18 End: 05/01/22 Due: 05/01/23

Endostar Continued Pumping Into Vein Combining With Gemcitabine-Carboplatin to Treat Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT01549093 Org: User:
Start: 08/31/11 End: 10/31/16 Due: 10/31/17